Form 4: Hologic Director Wendell Acquires Stock and Options

Director Amy McBride Wendell reports acquisition of Hologic common stock and stock options.

Summary

• On March 7, 2024, Amy McBride Wendell, a director of Hologic Inc., acquired 1,572 shares of common stock.
• These shares were obtained through restricted stock units that vest on the date of the 2025 Annual Meeting of Stockholders and are settled in shares of common stock on a one-for-one basis.
• Wendell also acquired 4,536 non-qualified stock options with an exercise price of $76.32, which become exercisable on the date of the 2025 Annual Meeting of Stockholders and expire on March 7, 2034.
• Following these transactions, Wendell directly owns 20,730 shares of Hologic common stock and 4,536 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating insider transactions. The acquisition of shares and options could be seen as a slightly positive sign, but it's not a major event.

Positives

• The director's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units vest and the options become exercisable on the date of the 2025 Annual Meeting of Stockholders.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The director's transactions may influence investor sentiment regarding Hologic's stock.

Key Dates